Efficacy and safety of paliperidone extended-release tablets in the treatment of schizophrenia / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
; (12): 566-569, 2018.
Article
en Zh
| WPRIM
| ID: wpr-701778
Biblioteca responsable:
WPRO
ABSTRACT
Objective To study the clinical effect and safety of paliperidone extended-release tablets in the treatment of schizophrenia.Methods 80 patients with schizophrenia were selected as the research subjects .Accord-ing to randomized single blind,the patients were divided into two groups ,40 cases in each group.The control group was given risperidone treatment,the observation group used paliperidone extended-release tablets treatment.The total effective rate,positive and negative symptoms score (PANSS score),mental disability score (WHO-DAS score II) and the incidence of adverse reactions were compared between the two groups .Results The clinical total effective rate (95.00%) in the observation group was significantly higher than the control group (80.00%,χ2 =4.114,P <0.05).After treatment, the PANSS score and WHO-DAS II score in the observation group were significantly decreased compared with before treatment (t =8.002,7.761,all P <0.05),which were lower than those in the control group after treatment (t =4.114,3.702,all P <0.05).The incidence rate of adverse reaction between the two groups had no statistically significant difference (7.50% vs.10.00%,χ2 =0.157,P >0.05).Conclusion The clinical efficacy of paliperidone extended-release tablets in the treatment of schizophrenia is significant ,which can effectively relieve patients with mental disorders ,and it is safe and reliable.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Clinical_trials
Idioma:
Zh
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Año:
2018
Tipo del documento:
Article